All In Biotech

NDA 022161 · Astellas

Lexiscan

Regadenoson · Intravenous · Adenosine Receptor Agonist

Novel

Last checked: Nov 19, 2026Latest source record: May 31, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Apr 10, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

66

8 Phase 3, 7 recruiting

FAERS reports

4,773

2,655 serious, 130 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 28, 2024.

LEXISCAN® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LEXISCAN · REGADENOSON 0.4MG/5ML (0.08MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Regadenoson" as an intervention, any sponsor and status, largest first.

All 66 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea511
  • dyspnoea409
  • injection site extravasation361
  • vomiting358
  • headache328
  • hypotension315
  • cardiac arrest284
  • dizziness276
  • seizure256
  • chest pain233
  • blood pressure decreased208
  • bradycardia196

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2008144
2009104
201076
201155
2012425
2013514
2014473
2015301
2016380
2017418
2018424
2019315
2020250
2021175
2022209
2023188
2024155
2025103
202664

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Lexiscan* (Regadenoson*) · HCPCS J2785

2024 spending

$15.3M

Beneficiaries

563,958

568,842 claims

Per beneficiary

$27

2024 ASP limit $6.90 per unit

View as table
YearSpending
2020$121,070,244
2021$131,961,556
2022$131,026,259
2023$118,734,034
2024$15,267,151

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 65 on PubMed

Sponsor: Astellas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.